Alphamab grants Ascletis rights to HBV candidate in Greater China; Expand their Partnership into Worldwide License Agreement
Alphamab Co. Ltd. licensed Ascletis Pharma Inc. exclusive rights to develop and commercialize KN035 (renamed ASC22) in China, Hong Kong, Macau, and Taiwan for viral diseases, including hepatitis B.
- Large Molecule
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com